A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to Febuxostat Administered Alone in Adult Subjects With Gout

Trial Profile

A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to Febuxostat Administered Alone in Adult Subjects With Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Verinurad (Primary) ; Colchicine; Febuxostat
  • Indications Gout
  • Focus Pharmacodynamics
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 31 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 12 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top